A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan for suppression of hepatitis activity and for prevention of disease progression in patients with hepatitis B virus- and HCV-induced chronic hepatitis. In Taiwan, SNMC has been licensed by Taiwan Food and Drug Administration for the indication of maintain hepatic function. Glycyrrhizin has been reported to mitigate hepatic inflammation by suppressing elevated alanine aminotransferase(ALT) levels and preventing disease progression. The effect of SNMC on acute deterioration of hepatic function following transarterial chemoembolization (TACE) was still unknown. This study aimed to evaluate the effect of SNMC on acute deterioration of hepatic function following TACE.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Series changes of serum levels of alanine aminotransferase
Timeframe: 4 days
Series changes of serum levels of aspartate aminotransferase
Timeframe: 4 days
Series changes of serum levels of Total bilirubin
Timeframe: 4 days
Series changes of Prothrombin Time
Timeframe: 4 days
Series changes of Prothrombin Time-Intemrnational Normalized Ratio
Timeframe: 4 days